http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 10 Sep 2026 14:20:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Sept. 10, 2026</chron></span> /PRNewswire/ -- <span value="LSE:HIK" idsrc="xmltag.org" >Hikma Pharmaceuticals PLC</span> (<span>Hikma, Group</span>) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of allergic reactions (anaphylaxis), have been accepted for review by regulators in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, and the <location value="LC/gb" idsrc="xmltag.org" >UK</location>. <span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span> has also filed a submission for its epinephrine nasal spray in <location value="LC/ca" idsrc="xmltag.org" >Canada</location>, with plans to expand filings beyond these markets in due course. </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html Thu, 10 Sep 2026 14:20:00 -0400 HKMPF HKMPY http://www.streetinsider.com/Press+Releases/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Sept. 10, 2026</chron></span> /PRNewswire/ -- <span value="LSE:HIK" idsrc="xmltag.org" >Hikma Pharmaceuticals PLC</span> (<span>Hikma, Group</span>) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of allergic reactions (anaphylaxis), have been accepted for review by regulators in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, and the <location value="LC/gb" idsrc="xmltag.org" >UK</location>. <span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span> has also filed a submission for its epinephrine nasal spray in <location value="LC/ca" idsrc="xmltag.org" >Canada</location>, with plans to expand filings beyond these markets in due course. </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html Thu, 10 Sep 2026 14:20:00 -0400 HKMPF HKMPY http://www.streetinsider.com/PRNewswire/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Sept. 10, 2026</chron></span> /PRNewswire/ -- <span value="LSE:HIK" idsrc="xmltag.org" >Hikma Pharmaceuticals PLC</span> (<span>Hikma, Group</span>) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of allergic reactions (anaphylaxis), have been accepted for review by regulators in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, and the <location value="LC/gb" idsrc="xmltag.org" >UK</location>. <span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span> has also filed a submission for its epinephrine nasal spray in <location value="LC/ca" idsrc="xmltag.org" >Canada</location>, with plans to expand filings beyond these markets in due course. </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html Thu, 10 Sep 2026 14:20:00 -0400 HKMPF HKMPY http://www.streetinsider.com/PRNewswire/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Sept. 10, 2026</chron></span> /PRNewswire/ -- <span value="LSE:HIK" idsrc="xmltag.org" >Hikma Pharmaceuticals PLC</span> (<span>Hikma, Group</span>) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of allergic reactions (anaphylaxis), have been accepted for review by regulators in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, and the <location value="LC/gb" idsrc="xmltag.org" >UK</location>. <span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span> has also filed a submission for its epinephrine nasal spray in <location value="LC/ca" idsrc="xmltag.org" >Canada</location>, with plans to expand filings beyond these markets in due course. </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html Thu, 10 Sep 2026 14:20:00 -0400 HKMPF HKMPY http://www.streetinsider.com/Intl+Ratings/Barclays+Upgrades+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+to+Equalweight/27032136.html <p>Barclays analyst James Gordon upgraded Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) from Underweight to Equalweight with a price target of GBP17.00 (from GBP13.50).</p><p>The analyst comments: “We upgrade from UW, to EW, as the execution shortfalls / downgrade cycle are apparently now at an end, cons expectations for H2’26 and ‘27 now look a little conservative to us, and valuation is still relatively undemanding. That said, we still have poor visibility and no mid-term outlook, while key management positions go unfilled. In addition, following improved execution at Q1/Q2, the valuation isn’t quite as appealing, in our view. We roll our PT http://www.streetinsider.com/Intl+Ratings/Barclays+Upgrades+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+to+Equalweight/27032136.html Tue, 08 Sep 2026 02:44:58 -0400 HKMPF http://www.streetinsider.com/Intl+Ratings/Barclays+Upgrades+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+to+Equalweight/27032136.html <p>Barclays analyst James Gordon upgraded Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) from Underweight to Equalweight with a price target of GBP17.00 (from GBP13.50).</p><p>The analyst comments: “We upgrade from UW, to EW, as the execution shortfalls / downgrade cycle are apparently now at an end, cons expectations for H2’26 and ‘27 now look a little conservative to us, and valuation is still relatively undemanding. That said, we still have poor visibility and no mid-term outlook, while key management positions go unfilled. In addition, following improved execution at Q1/Q2, the valuation isn’t quite as appealing, in our view. We roll our PT http://www.streetinsider.com/Intl+Ratings/Barclays+Upgrades+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+to+Equalweight/27032136.html Tue, 08 Sep 2026 02:44:58 -0400 HKMPF http://www.streetinsider.com/Upgrades/Barclays+Upgrades+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+to+Equalweight/27032136.html <p>Barclays analyst James Gordon upgraded Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) from Underweight to Equalweight with a price target of GBP17.00 (from GBP13.50).</p><p>The analyst comments: “We upgrade from UW, to EW, as the execution shortfalls / downgrade cycle are apparently now at an end, cons expectations for H2’26 and ‘27 now look a little conservative to us, and valuation is still relatively undemanding. That said, we still have poor visibility and no mid-term outlook, while key management positions go unfilled. In addition, following improved execution at Q1/Q2, the valuation isn’t quite as appealing, in our view. We roll our PT http://www.streetinsider.com/Upgrades/Barclays+Upgrades+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+to+Equalweight/27032136.html Tue, 08 Sep 2026 02:44:58 -0400 HKMPF http://www.streetinsider.com/Upgrades/Barclays+Upgrades+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+to+Equalweight/27032136.html <p>Barclays analyst James Gordon upgraded Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) from Underweight to Equalweight with a price target of GBP17.00 (from GBP13.50).</p><p>The analyst comments: “We upgrade from UW, to EW, as the execution shortfalls / downgrade cycle are apparently now at an end, cons expectations for H2’26 and ‘27 now look a little conservative to us, and valuation is still relatively undemanding. That said, we still have poor visibility and no mid-term outlook, while key management positions go unfilled. In addition, following improved execution at Q1/Q2, the valuation isn’t quite as appealing, in our view. We roll our PT http://www.streetinsider.com/Upgrades/Barclays+Upgrades+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+to+Equalweight/27032136.html Tue, 08 Sep 2026 02:44:58 -0400 HKMPF http://www.streetinsider.com/Analyst+Comments/Barclays+Upgrades+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+to+Equalweight/27032136.html <p>Barclays analyst James Gordon upgraded Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) from Underweight to Equalweight with a price target of GBP17.00 (from GBP13.50).</p><p>The analyst comments: “We upgrade from UW, to EW, as the execution shortfalls / downgrade cycle are apparently now at an end, cons expectations for H2’26 and ‘27 now look a little conservative to us, and valuation is still relatively undemanding. That said, we still have poor visibility and no mid-term outlook, while key management positions go unfilled. In addition, following improved execution at Q1/Q2, the valuation isn’t quite as appealing, in our view. We roll our PT http://www.streetinsider.com/Analyst+Comments/Barclays+Upgrades+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+to+Equalweight/27032136.html Tue, 08 Sep 2026 02:44:58 -0400 HKMPF http://www.streetinsider.com/Analyst+Comments/Barclays+Upgrades+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+to+Equalweight/27032136.html <p>Barclays analyst James Gordon upgraded Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) from Underweight to Equalweight with a price target of GBP17.00 (from GBP13.50).</p><p>The analyst comments: “We upgrade from UW, to EW, as the execution shortfalls / downgrade cycle are apparently now at an end, cons expectations for H2’26 and ‘27 now look a little conservative to us, and valuation is still relatively undemanding. That said, we still have poor visibility and no mid-term outlook, while key management positions go unfilled. In addition, following improved execution at Q1/Q2, the valuation isn’t quite as appealing, in our view. We roll our PT http://www.streetinsider.com/Analyst+Comments/Barclays+Upgrades+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+to+Equalweight/27032136.html Tue, 08 Sep 2026 02:44:58 -0400 HKMPF http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29/27027352.html <p>BofA Securities reiterated a Buy rating and GBP18.00 price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF).</p> http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29/27027352.html Fri, 04 Sep 2026 06:07:18 -0400 HKMPF http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29/27027352.html <p>BofA Securities reiterated a Buy rating and GBP18.00 price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF).</p> http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29/27027352.html Fri, 04 Sep 2026 06:07:18 -0400 HKMPF http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP2%2C025+at+Jefferies/26970188.html Jefferies analyst James Vane-Tempest raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP2,025.00 (from GBP1,870.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP2%2C025+at+Jefferies/26970188.html Tue, 25 Aug 2026 06:02:07 -0400 HKMPF http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP2%2C025+at+Jefferies/26970188.html Jefferies analyst James Vane-Tempest raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP2,025.00 (from GBP1,870.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP2%2C025+at+Jefferies/26970188.html Tue, 25 Aug 2026 06:02:07 -0400 HKMPF http://www.streetinsider.com/Analyst+PT+Change/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP2%2C025+at+Jefferies/26970188.html Jefferies analyst James Vane-Tempest raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP2,025.00 (from GBP1,870.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP2%2C025+at+Jefferies/26970188.html Tue, 25 Aug 2026 06:02:07 -0400 HKMPF http://www.streetinsider.com/Analyst+PT+Change/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP2%2C025+at+Jefferies/26970188.html Jefferies analyst James Vane-Tempest raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP2,025.00 (from GBP1,870.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP2%2C025+at+Jefferies/26970188.html Tue, 25 Aug 2026 06:02:07 -0400 HKMPF http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP18.70+at+Citi/26907931.html Citi analyst Giang Nguyen raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP18.70 (from GBP17.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP18.70+at+Citi/26907931.html Wed, 12 Aug 2026 04:37:24 -0400 HKMPF http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP18.70+at+Citi/26907931.html Citi analyst Giang Nguyen raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP18.70 (from GBP17.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP18.70+at+Citi/26907931.html Wed, 12 Aug 2026 04:37:24 -0400 HKMPF http://www.streetinsider.com/Analyst+PT+Change/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP18.70+at+Citi/26907931.html Citi analyst Giang Nguyen raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP18.70 (from GBP17.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP18.70+at+Citi/26907931.html Wed, 12 Aug 2026 04:37:24 -0400 HKMPF http://www.streetinsider.com/Analyst+PT+Change/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP18.70+at+Citi/26907931.html Citi analyst Giang Nguyen raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP18.70 (from GBP17.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP18.70+at+Citi/26907931.html Wed, 12 Aug 2026 04:37:24 -0400 HKMPF http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP21+at+Berenberg/26900111.html Berenberg analyst Victoria Lambert raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP21.00 (from GBP18.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP21+at+Berenberg/26900111.html Tue, 11 Aug 2026 04:50:08 -0400 HKMPF http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP21+at+Berenberg/26900111.html Berenberg analyst Victoria Lambert raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP21.00 (from GBP18.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP21+at+Berenberg/26900111.html Tue, 11 Aug 2026 04:50:08 -0400 HKMPF http://www.streetinsider.com/Analyst+PT+Change/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP21+at+Berenberg/26900111.html Berenberg analyst Victoria Lambert raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP21.00 (from GBP18.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP21+at+Berenberg/26900111.html Tue, 11 Aug 2026 04:50:08 -0400 HKMPF http://www.streetinsider.com/Analyst+PT+Change/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP21+at+Berenberg/26900111.html Berenberg analyst Victoria Lambert raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP21.00 (from GBP18.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP21+at+Berenberg/26900111.html Tue, 11 Aug 2026 04:50:08 -0400 HKMPF http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP20.50+at+Deutsche+Bank/26893139.html Deutsche Bank analyst Kane Slutzkin raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP20.50 (from GBP19.50) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Hikma+Pharmaceuticals+Plc+%28HIK%3ALN%29+%28HKMPF%29+PT+Raised+to+GBP20.50+at+Deutsche+Bank/26893139.html Mon, 10 Aug 2026 04:32:36 -0400 HKMPF